Similar Search Results

Pharmaceutical Innovation, Mortality Reduction, and Economic Growth

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 1998

We perform an econometric investigation of the contribution of pharmaceutical innovation to mortality reduction and … pharmaceutical innovation, there would have been no increase and perhaps even a small decrease in mean age at death, and that new … drugs have increased life expectancy, and lifetime income, by about 0.75-1.0% per annum. The drug innovation measures are …

Persistent link: https://www.econbiz.de/10005778568

The impact of new (orphan) drug approvals on premature mortality from rare diseases in the United States and France, 1999–2007

Lichtenberg, Frank - In: The European Journal of Health Economics 14 (2013) 1, pp. 41-56

This paper investigates the impact of the introduction of new orphan drugs on premature mortality from rare diseases using longitudinal, disease-level data obtained from a number of major databases. The analysis is performed using data from two countries: the United States (during the period...

Persistent link: https://www.econbiz.de/10010993861

Pharmaceutical Innovation and U.S. Cancer Survival, 1992-2003: Evidence from Linked SEER-MEDSTAT Data

Lichtenberg, Frank - In: Forum for Health Economics & Policy 10 (2008) 1, pp. 1090-1090

This study examines the impact of pharmaceutical innovation and other factors on the survival of U.S. cancer patients … other types of medical innovation, i.e. other pharmaceutical innovation, and innovation in surgical procedures, diagnostic … of rates of innovation in chemotherapy and other treatment and diagnostic procedures are constructed from the MEDSTAT …

Persistent link: https://www.econbiz.de/10005246214

Has Pharmaceutical Innovation Reduced Social Security Disability Growth?

Lichtenberg, Frank - In: International Journal of the Economics of Business 18 (2011) 2, pp. 293-316

relationship between disability recipiency and a good indicator of pharmaceutical innovation use: the mean vintage (FDA approval …

Persistent link: https://www.econbiz.de/10009275895

The effect of new cancer drug approvals on the life expectancy of American cancer patients, 1978-2004

Lichtenberg, Frank - In: Economics of Innovation and New Technology 18 (2009) 5, pp. 407-428

This study attempts to determine the extent to which new cancer drugs introduced during the last 40 years have prolonged the lives of Americans diagnosed with cancer. We use a difference-in-differences approach: we analyze the correlation across cancer sites (breast, prostate, lung, etc.)...

Persistent link: https://www.econbiz.de/10004966688

The Impact of New Drug Launches on Longevity: Evidence from Longitudinal, Disease-Level Data from 52 Countries, 1982–2001

Lichtenberg, Frank - In: International Journal of Health Care Finance and Economics 5 (2005) 1, pp. 47-73

We perform an econometric analysis of the effect of new drug launches on longevity, using data from the IMS Health Drug Launches database and the WHO Mortality Database. Under conservative assumptions, our estimates imply that the average annual increase in life expectancy of the entire...

Persistent link: https://www.econbiz.de/10005711017

The quality of medical care, behavioral risk factors, and longevity growth

Lichtenberg, Frank - In: International Journal of Health Care Finance and Economics 11 (2011) 1, pp. 1-34

Persistent link: https://www.econbiz.de/10008926030

Extreme Wage Inequality: Pay at the Very Top

Bell, Brian D.; Reenen, John Van - In: American Economic Review 103 (2013) 3, pp. 153-57

We provide new evidence on the growth in pay at the very top of the wage distribution in the United Kingdom. Sectoral decompositions show that workers in the financial sector have accounted for the majority of the gains at the top over the last decade. New results are also presented on the pay...

Persistent link: https://www.econbiz.de/10010815747

The Effect of New Drugs on Mortality from Rare Diseases and HIV

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2001

I investigate the effect of large increases in the number of drugs available to treat rare diseases and HIV on mortality associated with them. Mortality from both diseases declined dramatically following increases in drug approvals. Before the Orphan Drug Act went into effect (between 1979 and...

Persistent link: https://www.econbiz.de/10005720742

Sources of U.S. Longevity Increase, 1960-1997

Lichtenberg, Frank - National Bureau of Economic Research (NBER) - 2002

models using annual U.S. time-series data on life expectancy, health expenditure, and medical innovation. Reliable annual … data are available for only one type of innovation - new drugs - but pharmaceutical R&D accounts for a significant fraction … innovation (in the form of new drug approvals) and expenditure on medical care (especially public expenditure) contributed to …

Persistent link: https://www.econbiz.de/10005828594